Literature DB >> 26155392

The mutually regulatory loop of epithelial-mesenchymal transition and immunosuppression in cancer progression.

Limo Chen1, John V Heymach1, F Xiao-Feng Qin2, Don L Gibbons3.   

Abstract

Epithelial-mesenchymal transition and immunosuppression are crucial for cancer metastasis and treatment resistance. The mechanism by which these distinct processes are co-opted remains incompletely understood. Our recent work has exposed the "dirty affairs" of the 2 at the tumor site, thus calling for a combined therapy to break such a dangerous liaison.

Entities:  

Keywords:  epithelial–mesenchymal transition; immunosuppression; miRNA; therapy resistance; tumor microenvironment

Year:  2015        PMID： 26155392      PMCID： PMC4485725          DOI： 10.1080/2162402X.2014.1002731

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  Radiation enhances long-term metastasis potential of residual hepatocellular carcinoma in nude mice through TMPRSS4-induced epithelial-mesenchymal transition.

Authors:  T Li; Z-C Zeng; L Wang; S-J Qiu; J-W Zhou; X-T Zhi; H-H Yu; Z-Y Tang
Journal:  Cancer Gene Ther       Date:  2011-06-03       Impact factor: 5.987

2.  Immunotherapy exposes cancer stem cell resistance and a new synthetic lethality.

Authors:  Laszlo Radvanyi
Journal:  Mol Ther       Date:  2013-08       Impact factor: 11.454

3.  Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection.

Authors:  Santosh K Patnaik; Eric Kannisto; Steen Knudsen; Sai Yendamuri
Journal:  Cancer Res       Date:  2009-12-22       Impact factor: 12.701

4.  Epithelial to mesenchymal transition is a determinant of sensitivity to chemoradiotherapy in non-small cell lung cancer.

Authors:  Yasushi Shintani; Akira Okimura; Katsutoshi Sato; Tomoyuki Nakagiri; Yoshihisa Kadota; Masayohi Inoue; Noriyoshi Sawabata; Masato Minami; Naoki Ikeda; Kunimistu Kawahara; Tomoshige Matsumoto; Nariaki Matsuura; Mitsunori Ohta; Meinoshin Okumura
Journal:  Ann Thorac Surg       Date:  2011-10-31       Impact factor: 4.330

Review 5.  Immune promotion of epithelial-mesenchymal transition and generation of breast cancer stem cells.

Authors:  Jennifer M Reiman; Keith L Knutson; Derek C Radisky
Journal:  Cancer Res       Date:  2010-04-15       Impact factor: 12.701

Review 6.  Influence of IL-8 on the epithelial-mesenchymal transition and the tumor microenvironment.

Authors:  Claudia Palena; Duane H Hamilton; Romaine I Fernando
Journal:  Future Oncol       Date:  2012-06       Impact factor: 3.404

7.  Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression.

Authors:  Don L Gibbons; Wei Lin; Chad J Creighton; Zain H Rizvi; Philip A Gregory; Gregory J Goodall; Nishan Thilaganathan; Liqin Du; Yiqun Zhang; Alexander Pertsemlidis; Jonathan M Kurie
Journal:  Genes Dev       Date:  2009-09-15       Impact factor: 11.361

8.  M2-polarized tumor-associated macrophages promoted epithelial-mesenchymal transition in pancreatic cancer cells, partially through TLR4/IL-10 signaling pathway.

Authors:  Chao-Ying Liu; Juan-Ying Xu; Xiao-Yan Shi; Wei Huang; Ting-Yan Ruan; Ping Xie; Jun-Li Ding
Journal:  Lab Invest       Date:  2013-06-10       Impact factor: 5.662

9.  Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor.

Authors:  Benjamin Toh; Xiaojie Wang; Jo Keeble; Wen Jing Sim; Karen Khoo; Wing-Cheong Wong; Masashi Kato; Armelle Prevost-Blondel; Jean-Paul Thiery; Jean-Pierre Abastado
Journal:  PLoS Biol       Date:  2011-09-27       Impact factor: 8.029

10.  Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression.

Authors:  Limo Chen; Don L Gibbons; Sangeeta Goswami; Maria Angelica Cortez; Young-Ho Ahn; Lauren A Byers; Xuejun Zhang; Xiaohui Yi; David Dwyer; Wei Lin; Lixia Diao; Jing Wang; Jonathon Roybal; Mayuri Patel; Christin Ungewiss; David Peng; Scott Antonia; Melanie Mediavilla-Varela; Gordon Robertson; Milind Suraokar; James W Welsh; Baruch Erez; Ignacio I Wistuba; Lieping Chen; Di Peng; Shanshan Wang; Stephen E Ullrich; John V Heymach; Jonathan M Kurie; F Xiao-Feng Qin
Journal:  Nat Commun       Date:  2014-10-28       Impact factor: 14.919
  10 in total
  16 in total

Review 1.  Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways.

Authors:  Xue Bai; David E Fisher; Keith T Flaherty
Journal:  Nat Rev Clin Oncol       Date:  2019-09       Impact factor: 66.675

Review 2.  The Cellular Origin and Evolution of Breast Cancer.

Authors:  Mei Zhang; Adrian V Lee; Jeffrey M Rosen
Journal:  Cold Spring Harb Perspect Med       Date:  2017-03-01       Impact factor: 6.915

3.  PD-L1 and epithelial-mesenchymal transition in circulating tumor cells from non-small cell lung cancer patients: A molecular shield to evade immune system?

Authors:  Cristina Raimondi; Guido Carpino; Chiara Nicolazzo; Angela Gradilone; Walter Gianni; Alain Gelibter; Eugenio Gaudio; Enrico Cortesi; Paola Gazzaniga
Journal:  Oncoimmunology       Date:  2017-04-20       Impact factor: 8.110

4.  Growth and metastasis of lung adenocarcinoma is potentiated by BMP4-mediated immunosuppression.

Authors:  Limo Chen; Xiaohui Yi; Sangeeta Goswami; Young-Ho Ahn; Jonathon D Roybal; Yongbin Yang; Lixia Diao; Di Peng; David Peng; Jared J Fradette; Jing Wang; Lauren A Byers; Jonathan M Kurie; Stephen E Ullrich; F Xiao-Feng Qin; Don L Gibbons
Journal:  Oncoimmunology       Date:  2016-09-26       Impact factor: 8.110

5.  Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation.

Authors:  Chunying Song; Marco Piva; Lu Sun; Aayoung Hong; Gatien Moriceau; Xiangju Kong; Hong Zhang; Shirley Lomeli; Jin Qian; Clarissa C Yu; Robert Damoiseaux; Mark C Kelley; Kimberley B Dahlman; Philip O Scumpia; Jeffrey A Sosman; Douglas B Johnson; Antoni Ribas; Willy Hugo; Roger S Lo
Journal:  Cancer Discov       Date:  2017-09-01       Impact factor: 39.397

6.  Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.

Authors:  Willy Hugo; Jesse M Zaretsky; Lu Sun; Chunying Song; Blanca Homet Moreno; Siwen Hu-Lieskovan; Beata Berent-Maoz; Jia Pang; Bartosz Chmielowski; Grace Cherry; Elizabeth Seja; Shirley Lomeli; Xiangju Kong; Mark C Kelley; Jeffrey A Sosman; Douglas B Johnson; Antoni Ribas; Roger S Lo
Journal:  Cell       Date:  2016-03-17       Impact factor: 41.582

Review 7.  Advanced Melanoma: Resistance Mechanisms to Current Therapies.

Authors:  Alexandra M Haugh; April K S Salama; Douglas B Johnson
Journal:  Hematol Oncol Clin North Am       Date:  2020-10-26       Impact factor: 3.722

8.  The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer.

Authors:  Giuseppe Bronte; Maurizio Puccetti; Elisabetta Petracci; Lorenza Landi; Paola Cravero; Simona Scodes; Paola Ulivi; Sara Ravaioli; Maria Maddalena Tumedei; Marco Angelo Burgio; Federico Cappuzzo; Angelo Delmonte; Lucio Crinò; Sara Bravaccini
Journal:  Front Oncol       Date:  2021-05-04       Impact factor: 6.244

Review 9.  Immune Regulation and Antitumor Effect of TIM-1.

Authors:  Peng Du; Ruihua Xiong; Xiaodong Li; Jingting Jiang
Journal:  J Immunol Res       Date:  2016-06-20       Impact factor: 4.818

10.  The Z-cad dual fluorescent sensor detects dynamic changes between the epithelial and mesenchymal cellular states.

Authors:  M J Toneff; A Sreekumar; A Tinnirello; P Den Hollander; S Habib; S Li; M J Ellis; L Xin; S A Mani; J M Rosen
Journal:  BMC Biol       Date:  2016-06-17       Impact factor: 7.431
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.